{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dexamethasone+40+mg&page=2", "query": { "intervention": "Dexamethasone 40 mg", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dexamethasone+40+mg&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T18:01:37.397Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03412565", "title": "A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 265, "start_date": "2018-04-26", "completion_date": "2024-04-18", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-27T18:01:37.397Z", "location_count": 16, "location_summary": "Southington, Connecticut • Jacksonville, Florida • Orlando, Florida + 12 more", "locations": [ { "city": "Southington", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Southfield", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03412565" }, { "nct_id": "NCT04661137", "title": "A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Selinexor 60 MG", "type": "DRUG" }, { "name": "Selinexor 80 MG", "type": "DRUG" }, { "name": "Selinexor 100 MG", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hackensack Meridian Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2021-03-16", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-09-27T18:01:37.397Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Hackensack, New Jersey", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04661137" }, { "nct_id": "NCT00577668", "title": "A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Melphalan, Velcade, Thalidomide, Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2007-04", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2011-05-03", "last_synced_at": "2026-09-27T18:01:37.397Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00577668" }, { "nct_id": "NCT01505088", "title": "Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anterior Uveitis" ], "interventions": [ { "name": "40 mg/mL Dexamethasone phosphate ophthalmic solution", "type": "DRUG" }, { "name": "Prednisolone Acetate (1%) Eyedrops", "type": "DRUG" }, { "name": "100 mM sodium citrate buffer solution", "type": "DRUG" }, { "name": "Placebo Eyedrops", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eyegate Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "12 Years to 85 Years" }, "enrollment_count": 193, "start_date": "2011-12", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2013-03-29", "last_synced_at": "2026-09-27T18:01:37.397Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01505088" }, { "nct_id": "NCT02332850", "title": "Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Isatuximab", "type": "BIOLOGICAL" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Thomas Martin, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2015-01-21", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-09-27T18:01:37.397Z", "location_count": 5, "location_summary": "San Francisco, California • Denver, Colorado • Hackensack, New Jersey + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02332850" }, { "nct_id": "NCT04923893", "title": "A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Cilta-cel", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 743, "start_date": "2021-08-19", "completion_date": "2036-09-22", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-09-27T18:01:37.397Z", "location_count": 19, "location_summary": "San Francisco, California • New Haven, Connecticut • Miami, Florida + 13 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04923893" }, { "nct_id": "NCT06351644", "title": "ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed and/or Refractory Multiple Myeloma" ], "interventions": [ { "name": "ON 123300", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adriana Rossi", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2024-10-02", "completion_date": "2025-04-28", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-09-27T18:01:37.397Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06351644" }, { "nct_id": "NCT04514029", "title": "Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Simvastatin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 37, "start_date": "2020-08-06", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-09-27T18:01:37.397Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04514029" }, { "nct_id": "NCT07285239", "title": "Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Arm A: Belantamab Mafodotin", "type": "DRUG" }, { "name": "Arm B: Daratumumab Hyaluronidase", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PrECOG, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 500, "start_date": "2026-09", "completion_date": "2034-06", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-09-27T18:01:37.397Z", "location_count": 1, "location_summary": "La Crosse, Wisconsin", "locations": [ { "city": "La Crosse", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07285239" }, { "nct_id": "NCT01677858", "title": "A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2012-07-04", "completion_date": "2018-10-31", "has_results": true, "last_update_posted_date": "2022-09-23", "last_synced_at": "2026-09-27T18:01:37.397Z", "location_count": 35, "location_summary": "Tucson, Arizona • Bakersfield, California • Encinitas, California + 30 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01677858" } ] }